1. Introduction {#sec1-nutrients-08-00168}
===============

Metabolic syndrome is defined as a group of interrelated risk factors of metabolic origin that appear to directly promote the development of cardiovascular disease (CVD) \[[@B1-nutrients-08-00168]\]. The National Cholesterol Education Program's Adult Treatment Panel III report (NCEP ATPIII) \[[@B2-nutrients-08-00168]\] identified six components of metabolic syndrome that are related to CVD: (1) abdominal obesity; (2) atherogenic dyslipidemia; (3) elevated blood pressure; (4) insulin resistance; (5) proinflammatory state; and (6) prothrombotic state \[[@B2-nutrients-08-00168]\]. According to the ATP III criteria, a diagnosis of metabolic syndrome can be made when three out of five of the following characteristics are present: (1) abdominal obesity characterized by waist circumference (WC) \>102 cm for men and \>88 cm for women; (2) triglycerides (TG) ≥150 mg/dL; (3) HDL cholesterol (HDL) \<40 mg/dL for men and \<50 mg/dL for women; (4) blood pressure ≥130/≥85 mmHg; and (5) fasting glucose (FBG) ≥110 mg/dL \[[@B2-nutrients-08-00168]\]. Metabolic syndrome is a major health concern in the United States. Findings from the Third National Health and Nutrition Examination Survey (NHANES) suggest that according to the NCEP ATP III criteria approximately 34% of adults in the United States have metabolic syndrome \[[@B3-nutrients-08-00168]\].

Lifestyle therapies such as diet modification and physical activity are currently recommended as first-line interventions to reduce metabolic risk factors \[[@B1-nutrients-08-00168]\]. The Mediterranean-style diet (MedSD) is well-known for its cardio-protective benefits \[[@B4-nutrients-08-00168]\] and more recently, has been evaluated for the prevention and treatment of metabolic syndrome \[[@B5-nutrients-08-00168]\]. This dietary pattern emphasizes abundance of plant-based foods, a variety of minimally processed and locally grown foods, and olive oil as the principal source of fat \[[@B6-nutrients-08-00168]\]. The MedSD also includes daily consumption of low to moderate amounts of cheese and yogurt (low-fat and non-fat versions may be preferable), twice weekly consumption of fish and poultry, consumption of up to seven eggs per week, fresh fruit as dessert, red meat consumption limited to a few times a month, moderate consumption of wine (1 glass/day for women and 1--2 glasses/day for men) and regular physical activity at a level which promotes healthy weight and well-being \[[@B6-nutrients-08-00168]\].

To our knowledge, only one meta-analysis has evaluated literature on the effects of a MedSD on metabolic syndrome \[[@B7-nutrients-08-00168]\]. This meta-analysis included 35 clinical trials, two prospective studies, and 13 cross-sectional studies with a total of 534,906 participants and found an overall beneficial effect of the Mediterranean diet on reducing metabolic syndrome and its components in adults \[[@B7-nutrients-08-00168],[@B8-nutrients-08-00168]\]. Further, the Scientific Report of the 2015 \[[@B8-nutrients-08-00168]\] found dietary characteristics similar to that of a MedSD, including higher intake of vegetables, fruits, seafood, legumes, and nuts; moderate intake of alcohol (among adults); lower consumption of red and processed meat, and low intake of sugar-sweetened foods and drinks \[[@B8-nutrients-08-00168]\], to have a positive effect on metabolic syndrome risk factors (*i.e.*, blood pressure and lipid profiles). Taken together, the findings from the meta-analysis by Kastorini *et al.* \[[@B7-nutrients-08-00168]\] noted above and the 2015 Advisory Committee on the Dietary Guidelines for Americans \[[@B8-nutrients-08-00168]\] clearly support the positive effects of the MedSD on metabolic risk factors. However, it is currently unclear which specific characteristics of MedSD-based interventions significantly contribute to the previously observed beneficial effects of a traditional MedSD on metabolic risk factors. We therefore conducted a high quality meta-analysis with specific attention to each criteria of metabolic syndrome, each component of the MedSD, and each methodological characteristic which may help to explain the difference in results between published studies.

2. Methods {#sec2-nutrients-08-00168}
==========

2.1. Literature Search {#sec2dot1-nutrients-08-00168}
----------------------

The data sources were obtained following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement \[[@B9-nutrients-08-00168]\] guidelines. Original research studies that were published regardless of publication type until 9 February 2016 were included. Language was not restricted. Six computer databases were searched: PubMed, EMBASE (via Scopus), Web of Science, CINAHL, Agricola, and CAB Direct. A comprehensive literature search was conducted with the assistance of the University of Connecticut Health Sciences Librarian (JL) using combinations of Medical Subject Headings and other key words related to the aim of the study. Examples of the key words include: "Mediterranean Diet", "Mediterranean Style Diet", adiposity, "metabolic syndrome", overweight, BMI, "body mass", "waist circumference", obese, obesity, "abdominal fat", and "weight loss". The comprehensive search that was conducted for each database can be found in the supplemental material (S1). In addition to the electronic database search, all studies from Kastorini *et al.* \[[@B7-nutrients-08-00168]\] were screened and none of the studies overlap in both meta-analyses due to a difference in inclusion criteria.

2.2. Selection Criteria {#sec2dot2-nutrients-08-00168}
-----------------------

Studies had to meet the following criteria to be included: (1) report pre-and post-intervention data on waist circumference (any other metabolic risk factors were additional); and (2) focus on the MedSD as a whole dietary pattern. Studies were excluded if they (1) did not have pre- and post-intervention data on waist circumference; (2) focused on particular components of the Mediterranean diet, such as only olive oil; (3) included exercise in the intervention; (4) included participants \<18 years of age; (5) restricted calorie intake; and (6) did not report the information in a way that would allow effect sizes to be calculated using the published information. The relevance of studies was assessed by two independent researchers (M.G. and J.S.) with a hierarchical approach on the basis of title, abstract, and full manuscript. The original search resulted in 1696 abstracts with relevant key words. After screening and hand-searching articles, 29 articles (39 total comparisons) that used the traditional MedSD were included in analysis. Refer to [Figure 1](#nutrients-08-00168-f001){ref-type="fig"} for the PRISMA figure of included and excluded articles. A list of excluded articles is available in the supplemental material ([Table S1](#app1-nutrients-08-00168){ref-type="app"}).

2.3. Data Extraction {#sec2dot3-nutrients-08-00168}
--------------------

A comprehensive and detailed coding form and manual was created by a multidisciplinary team. The coding form includes approximately 330 variables for each study. Various characteristics were extracted from each study: (1) sample characteristics such as ethnicity, number and proportion of females, location of sample, and recruitment details; (2) intervention characteristics such as length of intervention, diet type, distribution of macronutrients, calorie intake, and participation in dietary counseling; and (3) study design characteristics such as number of interventions, type of control group, experimental conditions, and setting. The coding form was pilot-tested by two independent researchers (M.G. and J.S.) and was reviewed by additional experts (J.B., J.K., A.K., T.B.H.-M) before being finalized. The coding form and manual are available upon request to the corresponding author. All 30 studies were independently reviewed and coded by two researchers (M.G. and J.S.) and disagreements were solved by a third-party expert (T.B.H.-M).

2.4. Risk of Bias {#sec2dot4-nutrients-08-00168}
-----------------

The Cochrane Collaboration's tool for assessing risk of bias was used to assess risk of bias within individual studies \[[@B10-nutrients-08-00168]\]. In accordance with these guidelines, we report descriptions of internal and external validity summary ratings categorically, converting these to numerical scores as necessary for the purpose of meta-analytic moderator analysis.

Methodological quality (MQ) rankings have been identified as an under-analyzed element of the data reported in meta-analyses \[[@B11-nutrients-08-00168]\]. In this meta-analysis, MQ ratings based on the Cochrane risk of bias scale were entered as one or more possible moderators into the mixed-effects meta-regression models.

2.5. Statistical Analysis {#sec2dot5-nutrients-08-00168}
-------------------------

Inter-rater reliability was calculated for all continuous and categorical variables. The kappa (κ) coefficient was used to calculate categorical agreement \[[@B12-nutrients-08-00168]\] (kappa = 0.94, 96.9% agreement) and Pearson's correlation coefficient was used to calculate continuous agreement \[[@B13-nutrients-08-00168]\] (*r* = 1). We tested for asymmetries by using the Begg \[[@B14-nutrients-08-00168]\], Egger \[[@B15-nutrients-08-00168]\], and trim-and-fill \[[@B16-nutrients-08-00168]\] statistical tests as well as the funnel plot \[[@B17-nutrients-08-00168]\] graphical technique. Publication bias, descriptive statistics, and reliability tests were calculated using R version 3.1.2 \[[@B18-nutrients-08-00168]\] and particularly, "metafor" package \[[@B19-nutrients-08-00168]\] for all the meta-analytic analysis.

Effect sizes (ESs) were calculated for each outcome by calculating the standardized mean change \[[@B20-nutrients-08-00168]\] for each sample \[[@B21-nutrients-08-00168]\], using the standard deviation of the pretest and adjusting by small sample sizes. The data extracted to obtain the individual ESs could be means and standard deviations, F-ANOVA, *t*-test, or mean and standard deviation change. To uphold the assumption of independence, each outcome was analyzed independently when multiple outcomes were reported from the same study. Twenty-two studies report at least three outcomes with the most common outcomes being waist circumference, HDL cholesterol, and triglycerides. Fourteen studies reported all six outcomes of interest. A multivariate approach for multiple subsamples per study was not followed because no more than five comparisons were available per study. Multiple ESs were obtained from the same study when data was reported separately by participant and diet characteristics \[[@B22-nutrients-08-00168],[@B23-nutrients-08-00168]\]. Only two studies had subsamples based on sex \[[@B24-nutrients-08-00168],[@B25-nutrients-08-00168]\] and three studies had multiple subsamples for participant characteristics \[[@B26-nutrients-08-00168],[@B27-nutrients-08-00168],[@B28-nutrients-08-00168]\].

Weighted mean effect size by the inverse of the variance of each study was calculated across all studies under random- and fixed-effects assumptions \[[@B29-nutrients-08-00168]\]. To test for heterogeneity, Cochran's *Q* \[[@B30-nutrients-08-00168]\] and *I*^2^ \[[@B31-nutrients-08-00168]\] were calculated. To evaluate the sources of heterogeneity of the ESs, moderator analysis using weighted mixed-effects models with maximum likelihood estimation of the random-effects weights was performed testing each variable for study, intervention, and participant characteristics independently. The moving constant technique \[[@B32-nutrients-08-00168]\] was used to produce estimates of the ES (*d+*) at meaningful levels of the moderators and their Confidence Intervals (*Cis*) at different levels of interest. This technique was used to demonstrate results at the maximum and minimum values of significant moderators. Two-sided statistical significance was *p* \< 0.05. Finally, clinical units of measures were included by transforming arithmetically the standardized ES to its unstandardized version \[[@B33-nutrients-08-00168]\].

3. Results {#sec3-nutrients-08-00168}
==========

3.1. Description of Included Studies {#sec3dot1-nutrients-08-00168}
------------------------------------

A description of the included studies can be found in [Table 1](#nutrients-08-00168-t001){ref-type="table"}. Analysis of 29 reports shows that out of 4133 participants, 72% were female with a mean age of 46.93 (SD = 8.30). A majority of the studies were conducted in Europe (55.9%) and published in English (96.9%). Studies varied in design: 33.3% had a non-MedSD comparison group and 58.9% of studies were crossover or pre-/post-test only design. The mean publication year was 2009 (SD = 2.90) with a 12-year range from 2003 to 2015. The mean intervention length was 35.3 (SD = 50.71) weeks with a range from four to 208 weeks. No significant asymmetries were found using any of the statistical tests or the graphical funnel plot.

3.2. Effect Sizes {#sec3dot2-nutrients-08-00168}
-----------------

The traditional MedSD was found to have a significant beneficial effect on five out of six outcomes of interest ([Table 2](#nutrients-08-00168-t002){ref-type="table"}, [Figures S1--S6](#app1-nutrients-08-00168){ref-type="app"}). Overall ESs under random-effects assumptions indicate that the traditional MedSD had a significant overall effect on WC, TG, FBG, systolic blood pressure (SBP), and diastolic blood pressure (DBP) (*d~+~* = −0.54, 95% CI −0.77 to −0.31; *d~+~* = −0.46, 95% CI −0.72 to −0.21; *d~+~* = −0.50, 95% CI −0.81 to −0.20; *d~+~* = −0.72, 95% CI −1.03 to −0.42; *d~+~* = −0.94, 95% CI −1.45 to −0.44, respectively), but did not have a significant effect on HDL (*d~+~* = 0.19, 95% CI −0.07 to 0.46). There was large heterogeneity between studies with *I*^2^ ranging from 92.98% to 98.42%.

3.3. Moderator Analysis {#sec3dot3-nutrients-08-00168}
-----------------------

All moderation effects are presented in [Table 3](#nutrients-08-00168-t003){ref-type="table"}. In regards to study characteristics, trending associations were found for study region. Studies conducted in Europe showed significant beneficial effects from the traditional MedSD intervention on four of the metabolic risk factors (waist circumference, HDL cholesterol, triglycerides and fasting blood glucose) whereas studies conducted in the United States did not result in significant effect sizes for any of the study characteristics.

Significant associations were found for study design waist circumference, HDL cholesterol, triglycerides, fasting blood glucose and systolic blood pressure. Studies that included a comparison intervention group design (*i.e.*, a different type of diet) had more beneficial significant effect sizes favoring the MedSD compared to those studies using a traditional pre-/post-design or a crossover design.

Studies with a higher *Impact per Publication* (IPP) value showed more significant beneficial effects for waist circumference, HDL cholesterol, triglycerides, and fasting blood glucose with significant positive associations for each.

The length of the intervention (in weeks) significantly explained between 27.89% and 51.13% of the variability between studies for the following outcomes: waist circumference, HDL cholesterol, triglycerides, fasting blood glucose and systolic blood pressure. There was a significant positive association for length of intervention for all six outcomes of interest ([Figures S7--S11](#app1-nutrients-08-00168){ref-type="app"}). The longer the length of the intervention, the more significant the beneficial effect in favor of the traditional MedSD. Additional significant or trending intervention characteristics included the use of a behavioral technique, supervision, and dietary interventions conducted primarily in small groups. The use of a behavioral technique resulted in trending or significant beneficial effects in all of the outcomes of interest compared to the effects when there was no behavioral technique used.

The level of intervention or supervision during the study (*i.e.*, primarily one-on-one or small groups) resulted in significant or trending associations for waist circumference, HDL cholesterol, triglycerides, fasting blood glucose and systolic blood pressure. Interventions consisting of small groups saw significant beneficial effects for all six outcomes, whereas interventions that were primarily one-on-one resulted in only two significant outcomes.

In regards to specific components of the traditional MedSD interventions, specific macronutrient proportions of the diet, assessment of dietary compliance and participant engagement in dietary counseling did not significantly explain the variability between studies. Participant characteristics, in particular the presence or absence of certain disease states, were also analyzed as moderators. Disease states that were included in this analysis were cardiovascular disease, type II diabetes mellitus, metabolic syndrome, and overweight/obesity. These variables were not considered to be significant moderators.

3.4. Risk of Bias {#sec3dot4-nutrients-08-00168}
-----------------

Risk of bias was unclear for random sequence generation, allocation, blinding, incomplete outcome data, selective reporting, and other potential sources of bias ([Figure S12](#app1-nutrients-08-00168){ref-type="app"}). Moderator analysis was not significant for any of the risk of bias parameters (data not shown). No high or low risk of bias was found for random sequence generation and 3.3% of the articles had low risk of bias for allocation concealment. As for blinding of participants and personnel, 6.7% of the articles had low risk of bias and 13.3% of the articles had high risk of bias. Blinding of outcome assessment had 10% low risk of bias and 10% high risk of bias. Incomplete outcome data in the short-term and long-term both resulted in 6.7% of articles with high risk of bias. No high or low risk of bias was reported for selective reporting. With regard to other bias, 3.3% of articles had low risk of bias whereas 10% had high risk of bias.

4. Discussion {#sec4-nutrients-08-00168}
=============

The present meta-analysis of 29 intervention trials found that the traditional MedSD has significant beneficial effects for five out of six of the metabolic risk factors: waist circumference, triglycerides, fasting blood glucose, systolic blood pressure and diastolic blood pressure. The significant heterogeneity between studies was partly attributed to the location of the studies, the length of the intervention, and the IPP value of the journal where the study was published. Significant beneficial associations were found for studies conducted in Europe, those of longer duration, studies using a behavioral technique, studies with a comparison intervention group, and studies conducted primarily in groups for most of the metabolic risk factors. To our knowledge, this is the first meta-analysis to evaluate the effects of the Mediterranean diet on metabolic syndrome that meets 100% of the AMSTAR criteria \[[@B58-nutrients-08-00168]\].

Our findings that a traditional MedSD is beneficial in reducing the risk of CVD-associated metabolic parameters complements and extends previous work in this area. Several recent systematic reviews and meta-analyses published on the MedSD and CVD risk have reported similar positive effects on HDL cholesterol \[[@B59-nutrients-08-00168]\], triglycerides \[[@B59-nutrients-08-00168]\], systolic blood pressure \[[@B60-nutrients-08-00168],[@B61-nutrients-08-00168]\], diastolic blood pressure \[[@B60-nutrients-08-00168],[@B61-nutrients-08-00168]\], and fasting blood glucose \[[@B60-nutrients-08-00168]\]. These studies also found similar significant positive associations in moderator analysis for studies conducted in Mediterranean countries \[[@B7-nutrients-08-00168],[@B62-nutrients-08-00168]\], duration of study \[[@B7-nutrients-08-00168]\], study design \[[@B62-nutrients-08-00168]\], and study quality \[[@B4-nutrients-08-00168],[@B7-nutrients-08-00168]\].

To our knowledge, only one meta-analysis has been published on the effects of the Mediterranean diet on metabolic syndrome \[[@B7-nutrients-08-00168]\]. The meta-analysis by Kastorini *et al.* \[[@B7-nutrients-08-00168]\] included 35 clinical trials, two prospective studies, and 13 cross-sectional studies with a total of 534,906 participants. Consistent with our current analysis, Kastorini *et al.* found that the MedSD was associated with reductions in waist circumference, triglycerides and fasting glucose levels. The MedSD was also associated with beneficial effects on HDL cholesterol, whereas there were no association for systolic and diastolic blood pressure \[[@B7-nutrients-08-00168]\]. However, in the present meta-analysis we did not find a significant effect for HDL cholesterol and found a significant beneficial association for both systolic and diastolic blood pressure. The literature search employed by Kastorini *et al.* \[[@B7-nutrients-08-00168]\] differed from the current meta-analysis in that the search was limited to those manuscripts published in English and to three computer databases. Small literature searches of only a few key terms at a time were conducted rather than one comprehensive literature search. Clinical trials with lack of randomization, lack of a control diet group, and interventions without inclusion of all traditional Mediterranean diet components were excluded from their analysis \[[@B7-nutrients-08-00168]\]. For the present meta-analysis, a comprehensive literature search was performed using six electronic databases, language was not restricted and studies without comparison groups or with a lack of randomization were not excluded. Thus, differences in search criteria may have contributed to the reported discrepancies in the associations for the MedSD and HDL cholesterol and the MedSD and blood pressure between the present report and meta-analysis by Kastorini *et al.* \[[@B7-nutrients-08-00168]\].

Study Limitation and Strengths
------------------------------

Our meta-analysis had several limitations. There is significant heterogeneity between studies that could not be explained by the moderators included in our analyses. The data reported in our sample of studies did not allow us to control for baseline physical activity or different types and duration of on-going exercise, and thus, physical activity could not be included as a moderator. Weight loss was not the objective in any of the included studies, however, we did not control for weight change among participants. Lastly, ecological fallacy is a possibility as we did not have access to the raw data from the included studies and should be cautious interpreting the group results as individual effects. There are also multiple strengths for this meta-analysis. We used a comprehensive literature search in six electronic databases and an inclusive and comprehensive coding form and manual were used for data extraction. We performed moderation analysis on all variables with sufficient data provided in the published material. We excluded interventions that included exercise, which we believed would have precluded us from solely evaluating diet-associated effects. To our knowledge, this is the first meta-analysis to find significant beneficial associations for MedSD interventions that use behavioral techniques and small group interventions and metabolic risk factors. Lastly, we were able to use the moving constant technique and a predictive model to calculate effect sizes for each significant moderator and transform that effect size into clinical units of measure.

5. Conclusions {#sec5-nutrients-08-00168}
==============

The results of the present meta-analysis suggest that the traditional MedSD can have risk reduction effects on a number of metabolic parameters. In addition, the MedSD was significantly beneficial for different metabolic risk factors when, in general the intervention was longer in duration, the study was conducted in Europe, the report was published in a journal with higher Impact per Publication value, the study included a comparison intervention, a behavioral technique was used, and the study was conducted using small groups. More high-quality intervention studies conducted in non-European countries that control for physical activity and changes in weight, and include objective measures of compliance are warranted and would allow for further moderator analyses.
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nutrients-08-00168-t001_Table 1

###### 

Description of Included Studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                            Country         *N*    \% F   Age    Diseases                   Recruit-ment                     Dietary Assessment                                  Type of Diet            Duration (Weeks)   Control                         Outcome
  ---------------------------------------------------------------- --------------- ------ ------ ------ -------------------------- -------------------------------- --------------------------------------------------- ----------------------- ------------------ ------------------------------- -------------------------------
  Aizawa, *et al.* (2009) \[[@B26-nutrients-08-00168]\]            Canada          63     51%    53.9   PDM\                       Physician referral               Group, unsupervised                                 MedSD                   24                 No carotid artery stiffness     Carotid artery stiffness
                                                                                                        PHTN                                                                                                                                                                                       

  Bedard, *et al.* (2012) \[[@B27-nutrients-08-00168]\]            Canada          67     NR     39     Ob (57%)                   NR                               Individual, supervised                              MedSD                   8                  Non-Ob                          CVDRF

  Bekkouche, *et al.* (2014) \[[@B34-nutrients-08-00168]\]         Algeria         86     NR     52     MS (67%)                   Hospital                         Individual, unsupervised                            MedSD                   12                 No MS, healthy                  IR, OS, Inflam.

  Bos, *et al.* (2010) \[[@B35-nutrients-08-00168]\]               Netherlands     60     NR     52.5   Ob (100%)                  NR                               Individual, unsupervised                            MedSD                   10                 High SFA diet; High MUFA diet   Serum lipids, IS

  Connolly, *et al.* (2011) \[[@B28-nutrients-08-00168]\]          Great Britain   206    42%    60.4   CVD or CVDRF (100%)        Hospital, physician referral     Individual, unsupervised                            MedSD                   16                 None                            CVDRF

  Corbalan, *et al.* (2009) \[[@B36-nutrients-08-00168]\]          Spain           1406   82%    39     Ob (100%)                  Clinic referral                  Individual, unsupervised                            MedSD                   34                 None                            WT

  Esposito, *et al.* (2006) \[[@B37-nutrients-08-00168]\]          Italy           65     0%     43.9   MS, ED (100%)              Research database                Individual, unsupervised                            MedSD                   24                 Regular diet                    IIEF score

  Esposito, *et al.* (2007) \[[@B38-nutrients-08-00168]\]          Italy           59     100%   41.9   MS, FSD (100%)             Research Database                Individual, unsupervised                            MedSD                   24                 Regular Diet                    FSFI score

  Esposito, *et al.* (2004) \[[@B39-nutrients-08-00168]\]          Italy           180    45%    43.9   MS (100%)                  Clinic                           Group, unsupervised                                 MedSD                   104                Regular Diet                    Endo func, Vas Infl

  Esposito, *et al.* (2009) \[[@B40-nutrients-08-00168]\]          Italy           215    51%    52.2   NIDDM (100%)               Clinic                           Group, unsupervised                                 MedSD                   208                LF Diet                         Glycemic control

  Goulet, *et al.* (2003) \[[@B41-nutrients-08-00168]\]            Canada          77     100%   47     None, healthy              Newspaper ad.                    Individual, unsupervised                            MedSD                   12                 None                            Serum lipid, WT

  Goulet, *et al.* (2007) \[[@B42-nutrients-08-00168]\]            Canada          77     100%   46.7   None, healthy              Newspaper ad.                    Individual, unsupervised                            MedSD                   24                 None                            WT

  Jones, *et al.* (2011) \[[@B43-nutrients-08-00168]\]             United States   89     100%   47.5   MS (100%)                  NR                               Individual, unsupervised                            MedSD-MF                12                 MD, no MF                       MS RF

  Kolomvotsou, *et al.* (2013) \[[@B44-nutrients-08-00168]\]       Greece          90     48%    50.4   Ob (100%)                  Hospital                         Individual, unsupervised                            MedSD                   8                  Regular diet                    AO intake, plasma AO capacity

  Leblanc, *et al.* (2014) \[[@B45-nutrients-08-00168]\]           Canada          108    47%    41.4   Ob, MS (100%)              Media advertise-ments            Individual and group, unsupervised and supervised   MedSD                   12                 None                            Dietary intake, Met profile

  Leighton, *et al.* (2009) \[[@B46-nutrients-08-00168]\]          Chile           145    0%     39     MS (24%)                   Maestranza Diesel                Group, supervised                                   MedSD                   52                 None                            MS RF

  Lerman, *et al.* (2010) \[[@B47-nutrients-08-00168]\]            United States   24     83%    54.4   MS and high LDL-C (100%)   Previous study by Lerman         NR                                                  MedSD-MF                12                 MD, no MF                       Plasma lipids

  Lindeberg, *et al.* (2007) \[[@B48-nutrients-08-00168]\]         Sweden          29     0%     61     IHD, IGT, NIDDM            Hospital                         Individual, unsupervised                            MedSD                   12                 Paleolithic Diet                WT, serum glucose

  Llaneza, *et al.* (2010) \[[@B49-nutrients-08-00168]\]           Spain           116    100%   56.4   IR (100%)                  Hospital                         Group, unsupervised                                 MedSD, soy supplement   104                MD, no supp                     IR

  Papandreou, *et al.* (2012 \[[@B50-nutrients-08-00168]\]         Greece          40     NR     41.5   Ob, OSAS (100%)            University Medical School        Group, unsupervised                                 MedSD                   26                 Prudent Diet                    OSAS

  Papandreou, *et al.* (2012) \[[@B51-nutrients-08-00168]\]        Greece          21     NR     41.5   Ob, OSAS (100%)            University Medical School        Group, unsupervised                                 MedSD                   26                 Prudent Diet                    TBARS

  Rallidis, *et al.* (2009) \[[@B52-nutrients-08-00168]\]          Greece          82     48%    50.4   Ob (100%)                  Hospital                         Individual, unsupervised                            MedSD                   8                  Regular Diet                    Endo func

  Richard, *et al.* (2011) \[[@B53-nutrients-08-00168]\]           Canada          26     0%     49.4   MS (100%)                  NR                               Individual, unsupervised                            MedSD                   35                 Western Diet                    CVDRF

  Rubenfire, *et al.* (2011) \[[@B24-nutrients-08-00168]\]         United States   126    68%    51     MS (100%)                  Physician referral               Individual, unsupervised                            MedSD                   12                 None                            WT, BP, TG, serum glucose

  Ryan, *et al.* (2013) \[[@B54-nutrients-08-00168]\]              Australia       12     50%    55     NAFLD (100%)               Hospital                         Individual, unsupervised                            MedSD                   6                  LF diet                         WT, IS

  Sanchez-Benito, *et al.* (2012) \[[@B55-nutrients-08-00168]\]    Spain           158    87%    48     OverWT (100%)              Pharmacy office                  Individual, unsupervised                            MedSD                   26                 None                            BMI, BP, cholesterol

  Stendall-Hollis, *et al.* (2013) \[[@B56-nutrients-08-00168]\]   United States   129    100%   29.7   OverWT (100%)              Magazine, hospital, Craigslist   Individual, unsupervised                            MedSD                   16                 MyPyramid for P & B             WT, Inflam Bio

  Timar, *et al.* (2013) \[[@B25-nutrients-08-00168]\]             Romania         223    50%    55     NIDDM (100%)               Diabetes Center                  Group, unsupervised                                 MedSD                   52                 Diabetic Diet                   Glycemic control, CVDRF

  Van Velden, *et al.* (2007) \[[@B57-nutrients-08-00168]\]        South Africa    12     25%    46     MS (100%)                  NR                               Group, unsupervised                                 MedSD with red wine     8                  MD without red wine             CVDRF
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note. *N*, number of participants at baseline; F, females; NR, not reported; OverWT, Overweight; Ob, Obesity; MedSD, Mediterranean Style Diet; PDM, Pre-diabetes mellitus; PHTN, Pre-hypertension; CVDRF, Cardiovascular Disease risk factors; MS, Metabolic Syndrome; OS, oxidative stress; NIDDM, Non-insulin Dependent Diabetes; IR, insulin resistance; Inflam, Inflammation; SFA, saturated fatty acid; IS, Insulin Sensitivity; ED, Erectile Dysfunction; IIEF, International Index of Erectile Function; FSD, Female Sexual Dysfunction; FSFI, Female Sexual Function Index; Endo Func., endothelial function; Vas Infl, vascular inflammation; MedSD-MF, Low-Glycemic Mediterranean Diet with Medical Food; MS RF, Metabolic Syndrome Risk Factors; AO, antioxidant; WC, waist circumference; IHD, ischaemic heart disease; IGT, impaired glucose tolerance; OSAS, Obstructive Sleep Apnea Syndrome; TBARS, thiobarbituric acid reacting substances; BP, blood pressure; TG, serum triglycerides; Inflam Bio, inflammatory biomarkers; MyPyramid for P&B, USDA MyPyramid Diet for Pregnant and Breastfeeding Women; FVII, activated factor VII; MI, Myocardial Infarction; Met profile, metabolic profile.

Note on Dietary Assessment column: *Individual:* A dietitian performed a dietary assessment, providing individualized needs for caloric intake and recommendations, for each participant.*Group:* The study provided general dietary recommendations for the participants, such as a range of servings of certain food groups, calories based on sex, as opposed to tailoring diets to individual needs based on weight and height.*Supervised:* Participants consumed foods in a supervised setting, where the researchers had control over participant food choices and quantity of food served.*Unsupervised:* Participants food consumption was unsupervised by researchers, such as eating at home.

nutrients-08-00168-t002_Table 2

###### 

Summary of Results, Overall Effect Sizes and Homogeneity.

  -----------------------------------------------------------------------------------------
  Outcome   *k*   *d*~+~ (95% CI)       Homogeneity of *d*'s                     
  --------- ----- --------------------- ---------------------- --------- ------- ----------
  WC        39    −0.44\                −0.54\                 390.1     96.39   \<0.0001
                  (−0.48 to −0.41) \*   (−0.77 to −0.31) \*                      

  HDL       27    0.15\                 0.19\                  294.6     93.95   \<0.0001
                  (0.09 to 0.21) \*     (−0.07 to 0.46)                          

  TG        25    −0.34\                −0.46\                 231.06    93.74   \<0.0001
                  (−0.40 to −0.28) \*   (−0.72 to −0.21) \*                      

  FBG       23    −0.37\                −0.50\                 281.18    96.69   \<0.0001
                  (−0.42 to −0.33) \*   (−0.81 to −0.20) \*                      

  SBP       25    −0.74\                −0.72\                 320.11    97.00   \<0.0001
                  (−0.78 to −0.70) \*   (−1.03 to −0.42) \*                      

  DBP       25    −0.99\                −0.94\                 2263.05   98.42   \<0.0001
                  (−1.06 to −0.93) \*   (−1.45 to −0.44) \*                      
  -----------------------------------------------------------------------------------------

Note: *d*~+~, overall effect size; WC, waist circumference; HDL, HDL cholesterol; TG, triglycerides, FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; \* indicates a significant effect; *k* represents the number of interventions for each outcome included in the analysis; *Q* represents Cochran's *Q* indicating significance of heterogeneity; *I*^2^ represents the magnitude of heterogeneity; *p*-value represents the significance of heterogeneity.

nutrients-08-00168-t003_Table 3

###### 

Significant Moderator Analysis Results.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Moderator                                               Outcome                  Category                 *k*                *d*~+~ (95% CI)    *R*^2^         *p*-Value       Clinical Unit of Measure
  ------------------------------------------------------- ------------------------ ------------------------ ------------------ ------------------ -------------- --------------- --------------------------
  **Study Characteristics**                                                                                                                                                      

  Region                                                  WC                       Europe                   19                 −0.49\             2.25%          0.19            −1.23 cm
                                                                                                                               (−1.23 to 0.24)                                   

  US                                                      7                        −0.33\                   2.90%              0.19               −0.83 cm                       
                                                                                   (−0.96 to 0.29)                                                                               

  HDL                                                     Europe                   10                       0.80\              19.3%              0.04           0.13 mmol/L     
                                                                                                            (0.04 to 1.57)                                                       

  US                                                      6                        −0.10\                   19.3%              0.04               −0.02 mmol/L                   
                                                                                   (−0.71 to 0.50)                                                                               

  TG                                                      Europe                   9                        −0.74\             4.11%              0.12           −0.35 mmol/L    
                                                                                                            (−1.46 to −0.03)                                                     

  US                                                      4                        −0.13\                   4.11%              0.12               −0.06 mmol/L                   
                                                                                   (−073 to 0.46)                                                                                

  FBG                                                     Europe                   9                        −0.74\             9.14%              0.15           −0.06 mmol/L    
                                                                                                            (−1.76 to 0.27)                                                      

  US                                                      3                        −0.18\                   9.14%              0.15               −0.01 mmol/L                   
                                                                                   (−1.05 to 0.69)                                                                               

  SBP                                                     Europe                   10                       −0.68\             0.36%              0.25           −3.21 mmol/L    
                                                                                                            (−1.83 to 0.47)                                                      

  US                                                      4                        −0.47\                   0.36%              0.25               −2.22 mmol/L                   
                                                                                   (−1.44 to 0.50)                                                                               

  DBP                                                     Europe                   10                       −1.13\             2.88%              0.24           −3.47 mmol/L    
                                                                                                            (−2.02 to 1.14)                                                      

  US                                                      4                        −0.44\                   2.88%              0.24               −1.35 mmol/L                   
                                                                                   (−1.95 to 0.74)                                                                               

  Study Design                                            WC                       MedSD *vs.* Other Diet   13                 −1.14\             28.71%         \<0.0001        −2.87 cm
                                                                                                                               (−1.49 to −0.78)                                  

  Pre/Post or Crossover                                   23                       −0.27\                   28.71%             \<0.0001           −0.68 cm                       
                                                                                   (−0.52 to −0.02)                                                                              

  HDL                                                     MedSD *vs.* Other Diet   9                        0.79\              45.64%             \<0.0001       0.13 mmol/L     
                                                                                                            (0.45 to 1.15)                                                       

  Pre/Post or Crossover                                   16                       −0.16\                   45.64%             \<0.0001           −0.16 mmol/L                   
                                                                                   (−0.42 to 0.09)                                                                               

  TG                                                      MedSD *vs.* Other Diet   8                        −0.98\             28.04%             0.008          −0.46 mmol/L    
                                                                                                            (−1.39 to −0.59)                                                     

  Pre/Post or Crossover                                   15                       −0.21\                   28.04%             0.008              −0.10 mmol/L                   
                                                                                   (−0.49 to 0.07)                                                                               

  FBG                                                     MedSD *vs.* Other Diet   7                        −1.13\             30.92%             \<0.0001       −0.09 mmol/L    
                                                                                                            (−1.59 to −0.66)                                                     

  Pre/Post or Crossover                                   14                       −0.27\                   30.92%             \<0.0001           −0.02 mmol/L                   
                                                                                   (−0.59 to 0.06)                                                                               

  SBP                                                     MedSD *vs.* Other Diet   7                        −1.37\             32.26%             \<0.0001       −6.47 mmHg      
                                                                                                            (−1.86 to −0.87)                                                     

  Pre/Post or Crossover                                   16                       −0.53\                   32.26%             \<0.0001           −2.69 mmHg                     
                                                                                   (−0.84 to −0.22)                                                                              

  DBP                                                     MedSD *vs.* Other Diet   7                        −1.32\             0.00%              0.004          −4.06 mmHg      
                                                                                                            (−2.31 to −0.32)                                                     

  Pre/Post or Crossover                                   16                       −0.87\                   0.00%              0.004              −2.67 mmHg                     
                                                                                   (−1.52 to −0.21)                                                                              

  Impact per Publication Metric                           WC                       0 (minimum)              39                 −0.18\             50.13%         \<0.0001        −0.45 cm
                                                                                                                               (−0.42 to 0.06)                                   

  16.104 (maximum)                                        39                       −1.89\                   50.13%             \<0.0001           −4.76 cm                       
                                                                                   (−2.43 to −1.37)                                                                              

  HDL                                                     0 (minimum)              26                       −0.03\             29.44%             0.0006         −0.005 mmol/L   
                                                                                                            (−0.31 to 0.26)                                                      

  16.104 (maximum)                                        26                       0.95\                    29.44%             0.0006             0.15 mmol/L                    
                                                                                   (0.38 to 1.52)                                                                                

  TG                                                      0 (minimum)              24                       −0.23\             22.65%             \<0.0001       −0.11 mmol/L    
                                                                                                            (−0.53 to 0.08)                                                      

  16.104 (maximum)                                        24                       −1.09\                   22.65%             \<0.0001           −0.52 mmol/L                   
                                                                                   (−1.68 to −0.52)                                                                              

  FBG                                                     0 (minimum)              22                       −0.13\             41.52%             0.0004         −0.01 mmol/L    
                                                                                                            (−0.45 to 0.19)                                                      

  16.104 (maximum)                                        22                       −1.45\                   41.52%             0.0004             −0.11 mmol/L                   
                                                                                   (−2.03 to −0.88)                                                                              

  SBP                                                     0 (minimum)              24                       −0.51\             13.10%             0.13           −2.41 mmHg      
                                                                                                            (−0.86 to −0.16)                                                     

  16.104 (maximum)                                        24                       −1.16\                   13.10%             0.13               −5.48 mmHg                     
                                                                                   (−1.84 to −0.49)                                                                              

  DBP                                                     0 (minimum)              23                       −0.69\             3.54%              0.18           −2.12 mmHg      
                                                                                                            (−1.37 to 0.02)                                                      

  16.104 (maximum)                                        23                       −1.77\                   3.54%              0.18               −5.44 mmHg                     
                                                                                   (−3.06 to −0.49)                                                                              

  **Intervention Characteristics**                                                                                                                                               

  Length of intervention (in weeks)                       WC                       4 weeks (minimum)        39                 −0.24\             46.18%         \<0.0001        −0.604 cm
                                                                                                                               (−0.45 to −0.03)                                  

  208 weeks (maximum)                                     39                       −2.50\                   46.18%             \<0.0001           −6.29 cm                       
                                                                                   (−3.29 to −1.71)                                                                              

  HDL                                                     4 weeks (minimum)        27                       −0.09\             48.04%             \<0.0001       −0.01 mmol/L    
                                                                                                            (−0.32 to 0.14)                                                      

  208 weeks (maximum)                                     27                       1.79\                    48.04%             \<0.0001           0.29 mmol/L                    
                                                                                   (1.06 to 2.53)                                                                                

  TG                                                      4 weeks (minimum)        25                       −0.19\             32.1%              0.0009         −0.09 mmol/L    
                                                                                                            (−0.46 to 0.07)                                                      

  208 weeks (maximum)                                     25                       −1.73\                   32.1%              0.0009             −0.83 mmol/L                   
                                                                                   (−2.51 to −0.95)                                                                              

  FBG                                                     4 weeks (minimum)        23                       −0.19\             51.13%             \<0.0001       −0.01 mmol/L    
                                                                                                            (−0.45 to 0.07)                                                      

  208 weeks (maximum)                                     23                       −2.22\                   51.1%              \<0.0001           −0.17 mmol/L                   
                                                                                   (−3.02 to −1.41)                                                                              

  SBP                                                     4 weeks (minimum)        25                       −0.45\             27.89%             0.0004         −2.12 mmHg      
                                                                                                            (−0.77 to −0.14)                                                     

  208 weeks (maximum)                                     25                       −2.04\                   27.89%             0.004              −9.63 mmHg                     
                                                                                   (−2.98 to −1.09)                                                                              

  DBP                                                     4 weeks (minimum)        25                       −0.67\             6.39%              0.10           −2.06 mmHg      
                                                                                                            (−1.26 to −0.08)                                                     

  208 weeks (maximum)                                     25                       −2.37\                   6.39%              0.10               −7.28 mmHg                     
                                                                                   (−4.15 to −0.59)                                                                              

  Number of Females                                       WC                       0 (minimum)              35                 −0.49\             0.00%          0.95            −1.23 cm
                                                                                                                               (−0.76 to −0.23)                                  

  1154 (maximum)                                          35                       −0.54\                   0.00%              0.95               −1.36 cm                       
                                                                                   (−1.91 to 0.83)                                                                               

  HDL                                                     0 (minimum)              25                       0.33\              0.00%              0.39           0.06 mmol/L     
                                                                                                            (−0.06 to 0.72)                                                      

  1154 (maximum)                                          25                       −3.43\                   0.00%              0.39               −0.56 mmol/L                   
                                                                                   (−11.69 to 4.83)                                                                              

  TG                                                      0 (minimum)              23                       −0.45\             0.00%              0.89           −0.22 mmol/L    
                                                                                                            (−0.87 to −0.03)                                                     

  1154 (maximum)                                          23                       −1.04\                   0.00%              0.91               −0.49 mmol/L                   
                                                                                   (−10.91 to 8.83)                                                                              

  FBG                                                     0 (minimum)              21                       −0.55\             0.00%              0.91           −0.04 mmol/L    
                                                                                                            (−0.91 to −0.19)                                                     

  1154 (maximum)                                          21                       −0.46\                   0.00%              0.91               −0.04 mmol/L                   
                                                                                   (−1.94 to 1.01)                                                                               

  SBP                                                     0 (minimum)              23                       −0.70\             0.00%              0.79           −3.31 mmHg      
                                                                                                            (−1.04 to −0.36)                                                     

  1154 (maximum)                                          23                       −0.91\                   0.00%              0.79               −4.29 mmHg                     
                                                                                   (−2.36 to 0.53)                                                                               

  DBP                                                     0 (minimum)              22                       −0.59\             67.92%             \<0.0001       −1.81 mmHg      
                                                                                                            (−0.95 to −0.25)                                                     

  1154 (maximum)                                          22                       −5.82\                   67.92%             \<0.0001           −17.89 mmHg                    
                                                                                   (−7.29 to −4.33)                                                                              

  Total sample size                                       WC                       12 (minimum)             39                 −0.54\             0.00%          0.97            −1.36 cm
                                                                                                                               (−0.81 to −0.26)                                  

  1406 (maximum)                                          39                       −0.56\                   0.00%              0.97               −1.41 cm                       
                                                                                   (−1.88 to 0.77)                                                                               

  HDL                                                     12 (minimum)             27                       −0.18\             13.29%             0.05           −0.03 mmol/L    
                                                                                                            (−0.63 to 0.27)                                                      

  1406 (maximum)                                          27                       5.69\                    13.29%             0.05               0.93 mmol/L                    
                                                                                   (0.10 to 11.29)                                                                               

  TG                                                      12 (minimum)             25                       −0.20\             4.55%              0.18           −0.09 mmol/L    
                                                                                                            (−0.66 to 0.26)                                                      

  1406 (maximum)                                          25                       −4.65\                   4.55%              0.18               −2.22 mmol/L                   
                                                                                   (−10.79 to 1.48)                                                                              

  FBG                                                     12 (minimum)             23                       −0.49\             0.00%              0.85           −0.04 mmol/L    
                                                                                                            (−0.84 to −0.15)                                                     

  1406 (maximum)                                          23                       −0.64\                   0.00%              0.85               −0.05 mmol/L                   
                                                                                   (−2.05 to −0.78)                                                                              

  SBP                                                     12 (minimum)             25                       −0.71\             0.00%              0.79           −3.35 mmHg      
                                                                                                            (−1.05 to −0.35)                                                     

  1406 (maximum)                                          25                       −0.93\                   0.00%              0.79               −4.39 mmHg                     
                                                                                   (−2.38 to 0.53)                                                                               

  DBP                                                     12 (minimum)             24                       −0.41\             72.14%             \<0.0001       −1.26 mmHg      
                                                                                                            (−0.73 to −0.09)                                                     

  1406 (maximum)                                          24                       −5.9\                    72.14%             \<0.0001           −18.14 mmHg                    
                                                                                   (−7.22 to −4.58)                                                                              

  Sample size of intervention group                       WC                       11 (minimum)             39                 −0.54\             0.00%          0.99            −1.36 cm
                                                                                                                               (−0.79 to −0.28)                                  

  1154 (maximum)                                          39                       −0.55\                   0.00%              0.99               −1.38 cm                       
                                                                                   (−1.93 to 0.82)                                                                               

  HDL                                                     11 (minimum)             27                       0.11\              0.00%              0.60           0.02 mmol/L     
                                                                                                            (−0.33 to 0.54)                                                      

  1154 (maximum)                                          27                       2.24\                    0.00%              0.60               0.37 mmol/L                    
                                                                                   (−5.41 to 9.89)                                                                               

  TG                                                      11 (minimum)             25                       −0.34\             0.00%              0.47           −0.16 mmol/L    
                                                                                                            (−0.76 to 0.07)                                                      

  1154 (maximum)                                          25                       −3.45\                   0.00%              0.47               −1.65 mmol/L                   
                                                                                   (−11.62 to 4.73)                                                                              

  FBG                                                     11 (minimum)             23                       −0.50\             0.00%              0.96           −0.04 mmol/L    
                                                                                                            (−0.84 to −0.17)                                                     

  1154 (maximum)                                          23                       −0.54\                   0.00%              0.96               −0.04 mmol/L                   
                                                                                   (−1.96 to 0.88)                                                                               

  SBP                                                     11 (minimum)             25                       −0.71\             0.00%              0.78           −3.35 mmHg      
                                                                                                            (−1.05 to −0.37)                                                     

  1154 (maximum)                                          25                       −0.93\                   0.00%              0.78               −4.39 mmHg                     
                                                                                   (−2.39 to 0.53)                                                                               

  DBP                                                     11 (minimum)             24                       −0.51\             71.80%             \<0.0001       −1.57 mmHg      
                                                                                                            (−0.82 to −0.20)                                                     

  1154 (maximum)                                          24                       −5.91\                   71.80%             \<0.0001           −18.17 mmHg                    
                                                                                   (−7.25 to −4.58)                                                                              

  Use of a behavioral technique                           WC                       No                       21                 −0.43\             0.00%          \<0.0001        −1.08 cm
                                                                                                                               (−0.74 to −0.11)                                  

  Yes                                                     18                       −0.66\                   0.00%              \<0.0001           −1.66 cm                       
                                                                                   (−1.00 to −0.33)                                                                              

  HDL                                                     No                       14                       −0.08\             13.88%             0.02           −0.01 mmol/L    
                                                                                                            (−0.42 to 0.26)                                                      

  Yes                                                     13                       0.48\                    13.88%             0.02               0.08 mmol/L                    
                                                                                   (0.13 to 0.83)                                                                                

  TG                                                      No                       14                       −0.27\             6.26%              0.0003         −0.13 mmol/L    
                                                                                                            (−0.61 to 0.06)                                                      

  Yes                                                     11                       −0.70\                   6.26%              0.0003             −0.33 mmol/L                   
                                                                                   (−1.08 to −0.33)                                                                              

  FBG                                                     No                       12                       −0.29\             4.51%              0.001          −0.02 mmol/L    
                                                                                                            (−0.71 to 0.12)                                                      

  Yes                                                     11                       −0.72\                   4.51%              0.001              −0.06 mmol/L                   
                                                                                   (−1.14 to −0.29)                                                                              

  SBP                                                     No                       13                       −0.53\             1.71%              \<0.0001       −2.50 mmHg      
                                                                                                            (−0.94 to −0.12)                                                     

  Yes                                                     12                       −0.94\                   1.71%              \<0.0001           −4.44 mmHg                     
                                                                                   (−1.37 to −0.51)                                                                              

  Level of intervention or supervision during the study   WC                       Primarily one-on-one     14                 −0.47\             17.28%         \<0.0001        −1.18 cm
                                                                                                                               (−0.83 to −0.11)                                  

  Small groups                                            9                        −1.14\                   17.28%             \<0.0001           −2.87 cm                       
                                                                                   (−1.58 to −0.69)                                                                              

  HDL                                                     Primarily one-on-one     8                        −0.18\             15.73%             0.03           −0.03 mmol/L    
                                                                                                            (−0.63 to 0.28)                                                      

  Small groups                                            9                        0.65\                    15.73%             0.03               0.11 mmol/L                    
                                                                                   (0.23 to 1.07)                                                                                

  TG                                                      Primarily one-on-one     8                        −0.14\             16.04%             \<0.0001       −0.07 mmol/L    
                                                                                                            (−0.55 to 0.27)                                                      

  Small groups                                            7                        −1.03\                   16.04%             \<0.0001           −0.49 mmol/L                   
                                                                                   (−1.45 to −0.59)                                                                              

  FBG                                                     Primarily one-on-one     7                        −0.19\             19.26%             0.0002         −0.01 mmol/L    
                                                                                                            (−0.69 to 0.32)                                                      

  Small groups                                            7                        −1.04\                   19.26%             0.0002             −0.08 mmol/L                   
                                                                                   (−1.54 to −0.55)                                                                              

  SBP                                                     Primarily one-on-one     9                        −0.48\             28.65%             \<0.0001       −2.26 mmHg      
                                                                                                            (−0.92 to −0.04)                                                     

  Small groups                                            7                        −1.43\                   28.65%             \<0.0001           −6.75 mmHg                     
                                                                                   (−1.93 to −0.94)                                                                              

  DBP                                                     Primarily one-on-one     9                        −0.37\             2.44%              0.002          −1.13 mmHg      
                                                                                                            (−1.19 to 0.46)                                                      

  Small groups                                            7                        −1.54\                   2.44%              0.002              −4.73 mmHg                     
                                                                                   (−2.48 to −0.60)                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: WC, waist circumference; HDL, HDL cholesterol; TG, triglycerides, FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; k is the number of interventions included in the analysis for each outcome; *R*^2^ indicates the percentage of heterogeneity that the moderator accounts for; *p*-value represents the significance of the moderation effect; Clinical Unit of Measure was calculated using a predictive model transforming arithmetically the standardized ES to its unstandardized version.
